Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms

Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms
Alpha-enolase (Eno) is an ubiquitary glycolytic enzyme enjoying a number of features that go nicely past its principal metabolic function of vitality provider throughout glycolysis. Eno is localized within the cytoplasm, but in addition expressed on the cell membrane, the place it binds plasminogen permitting its activation.
Its shorter kind, within the nucleus, acts as transcription issue. In inflammatory situations, Eno undergoes post-translational modifications, comparable to citrullination, oxidation and phosphorylation. Eno can be an autoantigen in several problems.
In truth, autoantibodies to Eno have been detected in rheumatoid arthritis, lupus nephritis, main glomerulonephritis, most cancers, infections and different problems, and in lots of instances they symbolize particular markers to be utilized in medical apply.
Anti-Eno antibodies within the totally different medical situations will not be equal: they differ in isotype and sometimes acknowledge totally different epitopes on the enzyme. IgG1 and IgG3 are prevalent in Rheumatoid Arthritis, IgG2 in Lupus nephritis and IgG4 in main autoimmune glomerulopathy.
This overview analyzes the traits of anti-Eno autoantibodies in autoimmune problems and most cancers, describing their high quality specificity and isotype restriction. The post-translational modifications which can be goal of autoantibodies are additionally mentioned, as they symbolize the premise for elucidating the molecular mechanisms chargeable for epitope era.
Regardless of a powerful quantity of experimental work on anti-Eno antibodies, it’s nonetheless essential to validate the usage of anti-Eno antibodies as biomarkers of chosen illnesses and lengthen the information on the mechanisms of anti-Eno autoantibody manufacturing. Methods that downmodulate the immune response to Eno might symbolize sooner or later novel approaches within the therapy of autoimmune problems.

Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated α-Enolase Peptides as a Perform of Epitope Construction and Composition

Rheumatoid arthritis (RA) is an autoimmune illness affecting roughly 1-2% of the world inhabitants. Along with the primary found serologic markers for RA, the rheumatoid components (RFs), anti-citrullinated protein antibodies (ACPAs) are much more particular for the illness in comparison with RFs and are present in 70-80% of RA affected person sera.
RA etiopathogenesis nonetheless must be elucidated, as various factors are proposed to be concerned, comparable to Epstein-Barr virus an infection. Therefore, understanding the interplay between ACPAs and their citrullinated peptide targets is related for a greater information of RA pathophysiology and for diagnostic functions.
On this examine, a cohort of RA sera, wholesome management sera and a number of sclerosis sera have been screened for reactivity to quite a lot of citrullinated peptides originating from α-enolase, pro-filaggrin, proteoglycan and Epstein-Barr nuclear antigen-2 by enzyme-linked immunosorbent assay.
ACPA reactivity to citrullinated α-enolase peptides was discovered to rely on peptide size and peptide conformation, favouring cyclic (disulfide bond) conformations for lengthy peptides and linear peptides for truncated ones. Further investigations in regards to the optimum peptide conformation for ACPA detection, using pro-filaggrin and EBNA-2 peptides, confirmed these findings, indicating a optimistic impact of cyclization of longer peptides of roughly 20 amino acids.
Furthermore, screening of the citrullinated peptides confirmed that ACPAs may be divided into two teams based mostly on their reactivity. Roughly 90% of RA sera acknowledge a number of peptide targets, being outlined as cross-reactive or overlapping reactivities, and whose reactivity to the citrullinated peptide is taken into account primarily to be backbone-dependent.
In distinction, roughly 10% acknowledge a single goal and are outlined as nonoverlapping, primarily relying on the particular amino acid side-chains within the epitope for a steady interplay. Collectively, this examine contributed to characterize epitope composition and construction for optimum ACPA reactivity and to acquire additional information in regards to the cross-reactive nature of ACPAs.

Analysis of systemic lupus erythematosus illness exercise utilizing anti-α-enolase antibody and RDW

The target of the examine was to research the worth of anti-α-enolase antibody (Ab) mixed with RDW in evaluating the exercise of systemic lupus erythematosus (SLE). Ranges of serum anti-α-enolase Ab and RDW have been detected in 193 SLE sufferers and 98 wholesome controls by ELISA and automated blood cell counter (XN9000), respectively.
Moreover, the correlation between anti-α-enolase Ab and RDW in evaluating the exercise of SLE was evaluated by correlation evaluation. The extent of anti-α-enolase Ab (9.16 ± 0.44 ng/mL in steady group and 10.26 ± 0.36 ng/mL in exercise group) was considerably larger than that within the wholesome management (7.05 ± 0.27 ng/mL).
The extent of RDW (12.92% ± 1.23% in steady group and 13.57% ± 2.12% in exercise group) was considerably larger than that within the wholesome management (12.46% ± 0.61%). The degrees of anti-α-enolase Ab or RDW in SLE sufferers have been positively correlated with SLEDAI-2 Okay rating (r= 0.75, r = 0.73), respectively.
In contrast with the anti-α-enolase Ab (AUC: 78.0%) or RDW (AUC:80.0%) alone, anti-α-enolase Ab mixed with RDW (AUC: 81.0%) had the very best of the effectiveness of evaluating exercise of SLE. These information urged that mixed anti-α-enolase Ab with RDW could be good biomarker to foretell the exercise of SLE in medical.

Most cancers-associated retinopathy Four years after surgical procedure for ovarian most cancers

A 71-year-old girl introduced with progressive, bilateral, blurred imaginative and prescient and nyctalopia for the final 6 months. Her previous medical historical past included complete hysterectomy and chemotherapy for ovarian most cancers Four years in the past, with out metastases.
 Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms
Optical coherence tomography revealed outer retinal layers’ thinning bilaterally, whereas diffuse retinal pigment epithelium abnormalities have been present in fundus autofluorescence. Full-field electroretinogram confirmed abnormalities in each a- and b-waves with important discount of retinal sensitivity, affecting nevertheless extra the rod system. The affected person was optimistic for alpha-enolase and was recognized with cancer-associated retinopathy (CAR), which developed 4-year main most cancers.
Computerized tomography scan revealed an enlarged para-aortic lymph node on the left kidney, and the affected person was began on chemotherapy, mixed with immunosuppressive therapy. In conclusion, CAR needs to be suspected in sufferers experiencing unexplained visible disturbances, particularly within the context of earlier most cancers.

Autoantibody profiles and medical affiliation in Thai sufferers with autoimmune retinopathy

Autoimmune retinopathy (AIR) is a uncommon immune-mediated irritation of the retina. The autoantibodies towards retinal proteins and glycolytic enzymes have been reported to be concerned within the pathogenesis. This retrospective cohort examine assessed the antiretinal autoantibody profiles and their affiliation with medical outcomes of AIR sufferers in Thailand.
We included 44 sufferers, 75% have been females, with the general median age of onset of 48 (17-74, IQR 40-55.5) years. Frequent medical displays have been nyctalopia (65.9%), blurred imaginative and prescient (52.3%), constricted visible area (43.2%), and nonrecordable electroretinography (65.9%). Underlying malignancy and autoimmune illnesses have been present in 2 and 12 feminine sufferers, respectively.
We discovered 41 autoantibodies, with anti-α-enolase (65.9%) exhibiting the very best prevalence, adopted by anti-CAII (43.2%), anti-aldolase (40.9%), and anti-GAPDH (36.4%).
Anti-aldolase was related to male gender (P = 0.012, OR 7.11, 95% CI 1.54-32.91). Anti-CAII confirmed important affiliation with age of onset (P = 0.025, 95% CI – 17.28 to – 1.24), whereas anti-α-enolase (P = 0.002, OR 4.37, 95% CI 1.83-10.37) and anti-GAPDH (P = 0.001, OR 1.87, 95% CI 1.32-2.64) have been considerably related to nonrecordable electroretinography.

Non-Neuronal Enolase / Alpha Enolase (ENO1) Antibody

20-abx242097
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Enolase 3 antibody

22360-100ul 100ul
EUR 390

enolase 1 antibody

22990-100ul 100ul
EUR 390

beta Enolase antibody

20R-2770 50 ug
EUR 281
Description: Rabbit polyclonal beta Enolase antibody

Enolase 3 antibody

70R-1218 100 ug
EUR 377
Description: Rabbit polyclonal Enolase 3 antibody

Enolase 3 antibody

70R-2263 50 ug
EUR 467
Description: Rabbit polyclonal Enolase 3 antibody

Alpha enolase antibody

70R-15182 100 ug
EUR 327
Description: Rabbit polyclonal Alpha enolase antibody

Beta Enolase antibody

70R-15252 100 ug
EUR 327
Description: Rabbit polyclonal Beta Enolase antibody

Gamma enolase antibody

70R-15407 100 ug
EUR 327
Description: Rabbit polyclonal Gamma enolase antibody

gamma Enolase antibody

10R-7471 100 ul
EUR 393
Description: Mouse monoclonal gamma Enolase antibody

gamma Enolase antibody

10R-7472 100 ul
EUR 393
Description: Mouse monoclonal gamma Enolase antibody

gamma Enolase antibody

10R-7473 100 ul
EUR 393
Description: Mouse monoclonal gamma Enolase antibody

Enolase Polyclonal Antibody

40884-100ul 100ul
EUR 252

Enolase Polyclonal Antibody

40884-50ul 50ul
EUR 187

Gamma enolase antibody

70R-49706 100 ul
EUR 244
Description: Purified Polyclonal Gamma enolase antibody

gamma enolase Antibody

20-abx009295
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

gamma enolase Antibody

20-abx134144
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

Alpha-enolase Antibody

20-abx141577
  • EUR 370.00
  • EUR 606.00
  • EUR 300.00
  • 100 ul
  • 200 ul
  • 50 ul
  • Shipped within 5-10 working days.

Enolase (ENO) Antibody

20-abx300124
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Enolase Polyclonal Antibody

ABP51265-003ml 0.03ml
EUR 158
  • Immunogen information: Synthesized peptide derived from the C-terminal region of human Enolase at AA range: 340-420
  • Applications tips:
Description: A polyclonal antibody for detection of Enolase from Human, Mouse, Rat. This Enolase antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Enolase at AA range: 340-420

Enolase Polyclonal Antibody

ABP51265-01ml 0.1ml
EUR 289
  • Immunogen information: Synthesized peptide derived from the C-terminal region of human Enolase at AA range: 340-420
  • Applications tips:
Description: A polyclonal antibody for detection of Enolase from Human, Mouse, Rat. This Enolase antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Enolase at AA range: 340-420

Enolase Polyclonal Antibody

ABP51265-02ml 0.2ml
EUR 414
  • Immunogen information: Synthesized peptide derived from the C-terminal region of human Enolase at AA range: 340-420
  • Applications tips:
Description: A polyclonal antibody for detection of Enolase from Human, Mouse, Rat. This Enolase antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Enolase at AA range: 340-420

Enolase Polyclonal Antibody

ES2264-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Enolase from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Enolase Polyclonal Antibody

ES2264-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Enolase from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Anti-Enolase antibody

STJ13100198 100 µl
EUR 427

Anti-Enolase antibody

STJ92926 200 µl
EUR 197
Description: Enolase is a protein encoded by the ENO2 gene which is approximately 47,2 kDa. Enolase is localised to the cytoplasm and cell membrane and is involved in glucose metabolism, carbon metabolism, HIF-1 signalling pathway and de-adenylation-dependent mRNA decay. It is one of the three enolase isoenzymes found in mammals. It has neurotrophic and neuroprotective properties on number of central nervous system neurons. It binds to cultured neocortical neurons in the presence of calcium and promotes cell survival. The enolase alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons. Mutations in the ENO2 gene can result in granular cell tumors, pediatric ovarian dysgerminoma and olfactory neuroblastoma. The antibody STJ92926 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of Enolase protein.

Human Enolase 2 Antibody

32702-05111 150 ug
EUR 261

Human Enolase 1 Antibody

32014-05111 150 ug
EUR 261

Non Neuronal Enolase antibody

10R-8640 100 ul
EUR 393
Description: Mouse monoclonal Non Neuronal Enolase antibody

Non Neuronal Enolase antibody

10R-8641 100 ul
EUR 393
Description: Mouse monoclonal Non Neuronal Enolase antibody

Alpha enolase antibody (HRP)

60R-1386 100 ug
EUR 327
Description: Rabbit polyclonal Alpha enolase antibody (HRP)

Alpha enolase antibody (FITC)

60R-1387 100 ug
EUR 327
Description: Rabbit polyclonal Alpha enolase antibody (FITC)

Alpha enolase antibody (biotin)

60R-1388 100 ug
EUR 327
Description: Rabbit polyclonal Alpha enolase antibody (biotin)
Affiliation between the antibody profiles and medical outcomes could also be used to direct and modify the therapy plans and supply insights within the pathogenesis of AIR.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

A MET-agonistic antibody accelerates cirrhotic liver regeneration and improves mouse survival following partial hepatectomy

A MET-agonistic antibody accelerates cirrhotic liver regeneration and improves mouse survival following partial hepatectomyA MET-agonistic antibody accelerates cirrhotic liver regeneration and improves mouse survival following partial hepatectomy

Small-for-size syndrome is a standard complication following partial liver transplantation and prolonged hepatectomy. Small-for-size syndrome is characterised by post-operative liver dysfunction attributable to inadequate regenerative capability and portal hyper-perfusion, and